The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Ultrasound Enhanced Delivery of Molecular Imaging and Therapeutic Agents in Alzheimer's Disease Mouse Models
Open accessAbstract
Alzheimer's disease is a neurodegenerative disorder typified by the accumulation of a small protein, beta-amyloid, which aggregates and is the primary component of amyloid plaques. Many new therapeutic and diagnostic agents for reducing amyloid plaques have limited efficacy in vivo because of poor transport across the blood-brain barrier. Here we demonstrate that low-intensity focused ultrasound with a microbubble contrast agent may be used to transiently disrupt the blood-brain barrier, allowing non-invasive, localized delivery of imaging fluorophores and immunotherapeutics directly to amyloid plaques. We administered intravenous Trypan blue, an amyloid staining red fluorophore, and anti-amyloid antibodies, concurrently with focused ultrasound therapy in plaque-bearing, transgenic mouse models of Alzheimer's disease with amyloid pathology. MRI guidance permitted selective treatment and monitoring of plaque-heavy anatomical regions, such as the hippocampus. Treated brain regions exhibited 16.5+/-5.4-fold increase in Trypan blue fluorescence and 2.7+/-1.2-fold increase in anti-amyloid antibodies that localized to amyloid plaques. Ultrasound-enhanced delivery was consistently reproduced in two different transgenic strains (APPswe:PSEN1dE9, PDAPP), across a large age range (9-26 months), with and without MR guidance, and with little or no tissue damage. Ultrasound-mediated, transient blood-brain barrier disruption allows the delivery of both therapeutic and molecular imaging agents in Alzheimer's mouse models, which should aid pre-clinical drug screening and imaging probe development. Furthermore, this technique may be used to deliver a wide variety of small and large molecules to the brain for imaging and therapy in other neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516 · cited 1×
“To test the robustness of FUS-MB across transgenic strains, we repeated the treatment described above in 26 month-old PDAPP mice (n = 2), which express a mutant form of APP that results in severe amyloidosis and accompanying pathology, including neuritic dystrophies, astrocytosis, and microgliosis”
MethodBard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
[ 11 C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease
Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036
Pike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., Mathis, C. A., Klunk, W. E., Masters, C. L., & Rowe, C. C. (2007) · Brain · doi:10.1093/brain/awm238 · Cited by 789
Hynynen, K., McDannold, N., Sheikov, N. A., Jolesz, F. A., & Vykhodtseva, N. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2004.06.046 · Cited by 679
Self-citationBard, F., Barbour, R., Cannon, C., Carretto, R., Fox, M., Games, D., Guido, T., Hoenow, K., Hu, K., Johnson-Wood, K., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0436286100 · Cited by 411
Blood—Brain Barrier Permeability Precedes Senile Plaque Formation in an Alzheimer Disease Model
UJIIE, M., DICKSTEIN, D. L., CARLOW, D. A., & JEFFERIES, W. A. (2003) · Microcirculation · doi:10.1038/sj.mn.7800212 · Cited by 351
Aβ peptide immunization restores blood‐brain barrier integrity in Alzheimer disease
Dickstein, D. L., Biron, K. E., Ujiie, M., Pfeifer, C. G., Jeffries, A. R., & Jefferies, W. A. (2006) · The FASEB Journal · doi:10.1096/fj.05-3956com · Cited by 111 · cited 2×
“Despite promising advances in immunotherapeutics [17,30,31,32,33] and PET imaging [34,35,36], Alzheimer’s disease remains intractable to current therapeutic and diagnostic strategies.”
Background
Cited by
Transcranial Pulsed Ultrasound Stimulates Intact Brain Circuits
Tufail, Y., Matyushov, A., Baldwin, N., Tauchmann, M. L., Georges, J., Yoshihiro, A., Tillery, S. I. H., & Tyler, W. J. (2010) · Neuron · doi:10.1016/j.neuron.2010.05.008 · Cited by 977
Blood-brain barrier opening in Alzheimer’s disease using MR-guided focused ultrasound
Lipsman, N., Meng, Y., Bethune, A. J., Huang, Y., Lam, B., Masellis, M., Herrmann, N., Heyn, C., Aubert, I., Boutet, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04529-6 · Cited by 950
Self-citationThe blood-brain barrier: Physiology and strategies for drug delivery
Pandit, R., Chen, L., & Götz, J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.11.009 · Cited by 651
Nanotechnological advances for the delivery of cns therapeutics.
Wong, H. L., Wu, X. Y., & Bendayan, R. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.10.007 · Cited by 488
Aryal, M., Arvanitis, C. D., Alexander, P. M., & McDannold, N. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.01.008 · Cited by 443
Self-citationEvolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
S. Hersh, D., S. Wadajkar, A., B. Roberts, N., G. Perez, J., P. Connolly, N., Frenkel, V., A. Winkles, J., F. Woodworth, G., & J. Kim, A. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666151221150733 · Cited by 387
“Sonication resulted in glial activation, enhanced the delivery of endogenous IgG and IgM antibodies [156], and facilitated the delivery of exogenous anti-amyloid antibodies [157, 158], resulting in reduced plaque number and size.”
Jordão, J. F., Ayala-Grosso, C. A., Markham, K., Huang, Y., Chopra, R., McLaurin, J., Hynynen, K., & Aubert, I. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010549 · Cited by 378
Self-citationMRI-Guided Focused Ultrasound Surgery
Jolesz, F. A. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.60.041707.170303 · Cited by 377
A Review of Low-Intensity Pulsed Ultrasound for Therapeutic Applications
Jiang, X., Savchenko, O., Li, Y., Qi, S., Yang, T., Zhang, W., & Chen, J. (2019) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2018.2889669 · Cited by 353
Jordão, J. F., Thévenot, E., Markham-Coultes, K., Scarcelli, T., Weng, Y.-Q., Xhima, K., O'Reilly, M., Huang, Y., McLaurin, J., Hynynen, K., et al. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.05.008 · Cited by 326
Self-citationFocused ultrasound-mediated drug delivery through the blood–brain barrier
Burgess, A., Shah, K., Hough, O., & Hynynen, K. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1028369 · Cited by 323
Self-citationCavitation microstreaming and stress fields created by microbubbles
Collis, J., Manasseh, R., Liovic, P., Tho, P., Ooi, A., Petkovic-Duran, K., & Zhu, Y. (2010) · Ultrasonics · doi:10.1016/j.ultras.2009.10.002 · Cited by 308
Treat, L. H., McDannold, N., Zhang, Y., Vykhodtseva, N., & Hynynen, K. (2012) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2012.04.015 · Cited by 296
Self-citationBurgess, A., Dubey, S., Yeung, S., Hough, O., Eterman, N., Aubert, I., & Hynynen, K. (2014) · Radiology · doi:10.1148/radiol.14140245 · Cited by 286
Self-citationLiu, H.-L., Fan, C.-H., Ting, C.-Y., & Yeh, C.-K. (2014) · Theranostics · doi:10.7150/thno.8074 · Cited by 276
Ultrasound treatment of neurological diseases — current and emerging applications
Leinenga, G., Langton, C., Nisbet, R., & Götz, J. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.13 · Cited by 275
Chen, H., & Konofagou, E. E. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.71 · Cited by 262
Choi, J. J., Feshitan, J. A., Baseri, B., Wang, S., Tung, Y.-S., Borden, M. A., & Konofagou, E. E. (2010) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2009.2034533 · Cited by 261
Koffie, R. M., Farrar, C. T., Saidi, L.-J., William, C. M., Hyman, B. T., & Spires-Jones, T. L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111405108 · Cited by 260
Nanomaterial based drug delivery systems for the treatment of neurodegenerative diseases
Masoudi Asil, S., Ahlawat, J., Guillama Barroso, G., & Narayan, M. (2020) · Biomaterials Science · doi:10.1039/d0bm00809e · Cited by 181
Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases
Barchet, T. M., & Amiji, M. M. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240902758188 · Cited by 145
Wang, A., Das, P., Switzer, R. C., Golde, T. E., & Jankowsky, J. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5077-10.2011 · Cited by 118
“Several groups are testing ways to increase the brain penetrance of peripherally delivered antibody, including polyamine modification or ultrasonic disruption of the blood– brain barrier (Poduslo et al., 2007; Choi et al., 2008; Raymond et al., 2008).”
BackgroundMicrobubble-Assisted Ultrasound for Drug Delivery in the Brain and Central Nervous System
Burgess, A., & Hynynen, K. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-22536-4_16 · Cited by 62
Self-citationRouhi, N., Chakeri, Z., Ghorbani Nejad, B., Rahimzadegan, M., Rafi Khezri, M., Kamali, H., & Nosrati, R. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37533 · Cited by 20
Metadata
- Authors
- Raymond, S. B., Treat, L. H., Dewey, J. D., McDannold, N. J., Hynynen, K., & Bacskai, B. J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-05-14
- Volume
- 3
- Issue
- 5
- Pages
- e2175
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2114072420
- Cited by
- 227
- References
- 8
- FWCI
- 9.17
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.